A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with Chronic Respiratory Disease.
Phase 4
- Conditions
- Patients with expectoration symptom in acute exacerbation of bronchial asthma or chronic obstructive pulmonary disease.
- Registration Number
- JPRN-UMIN000008534
- Lead Sponsor
- Kaken Pharmaceutical Co., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Not provided
Exclusion Criteria
-Patients with a history of drug hypersensitivity. -Patients with blood clotting defect. -Elderly patients with depressed physiological function and who are judged to be inadequate to participate in this trial by the principal investigator or co-investigator. -Patients who are needed domiciliary oxygen therapy. -Patients whose general status are quite worsened.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changing rate of FEV1
- Secondary Outcome Measures
Name Time Method